Luin tämmöisestä tutkimuksesta, jossa fibromyalgiaa sairastaville annettiin 3 mg melatoniinia nukkumaan mennessä ja neljän viikon kuluttua todettiin, että siitä oli ollut apua. Yritin ensin kääntää tekstin suomeksi, mutta en osannut, kun en oikein tunne tätä tautiakaan. Laitan sen tähän englanniksi, jos jotakuta kiinnostaa.
The effect of melatonin in patients with fibromyalgia: a pilot study.
The aim of the study was to determine the possible effect of
melatonin treatment on disturbed sleep, fatigue and pain symptoms
observed in fibromyalgia (FM) patients. Twenty-one consecutive patients
with FM were included in an open 4-week-duration pilot study. Before and
after treatment with melatonin 3 mg at bedtime, patients were evaluated
using tender point count by palpation of 18 classic anatomical regions,
pain score in four predesignated areas, pain severity on a 10 cm visual
analogue scale (VAS), sleep disturbances, fatigue, depression, anxiety,
and patient and physician global assessments, also by a VAS. Urine
6-sulphatoxymelatonin levels (aMT-6S) were measured in the patients and
20 age- and sex-matched controls. Nineteen patients completed the study.
One patient withdrew because of migraine and another was lost to
follow-up. At day 30, median values for the tender point count and
severity of pain at selected points, patient and physician global
assessments and VAS for sleep significantly improved with melatonin
treatment. Other variables improved but did not reach statistical
significance. Adverse events were mild and transient. Lower levels of
aMT-6S were found in FM patients compared with normal median controls
( /-SD, 9.16 /- 7.9 microg/24 h vs 16.8 /- 12.8 microg/24 h) (p =
0.06). Although this is an open study, our preliminary results suggest
that melatonin can be an alternative and safe treatment for patients
with FM. Double-blind placebo controlled studies are needed
The effect of melatonin in patients with fibromyalgia: a pilot study.
The aim of the study was to determine the possible effect of
melatonin treatment on disturbed sleep, fatigue and pain symptoms
observed in fibromyalgia (FM) patients. Twenty-one consecutive patients
with FM were included in an open 4-week-duration pilot study. Before and
after treatment with melatonin 3 mg at bedtime, patients were evaluated
using tender point count by palpation of 18 classic anatomical regions,
pain score in four predesignated areas, pain severity on a 10 cm visual
analogue scale (VAS), sleep disturbances, fatigue, depression, anxiety,
and patient and physician global assessments, also by a VAS. Urine
6-sulphatoxymelatonin levels (aMT-6S) were measured in the patients and
20 age- and sex-matched controls. Nineteen patients completed the study.
One patient withdrew because of migraine and another was lost to
follow-up. At day 30, median values for the tender point count and
severity of pain at selected points, patient and physician global
assessments and VAS for sleep significantly improved with melatonin
treatment. Other variables improved but did not reach statistical
significance. Adverse events were mild and transient. Lower levels of
aMT-6S were found in FM patients compared with normal median controls
( /-SD, 9.16 /- 7.9 microg/24 h vs 16.8 /- 12.8 microg/24 h) (p =
0.06). Although this is an open study, our preliminary results suggest
that melatonin can be an alternative and safe treatment for patients
with FM. Double-blind placebo controlled studies are needed
Vastaukset 1
Vanhimmat
Siis älkää ikänä kertoko lekurille että teillä on fibromyalgia todettu jos haluatte saada kunnon hoitoa.